𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma

✍ Scribed by Alissa Huston; Jason Brown; G. David Roodman

Book ID
113616226
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
49 KB
Volume
34
Category
Article
ISSN
0301-472X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bortezomib in combination with dexametha
Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience
✍ Weiyan Zheng; Guoqing Wei; Xiujin Ye; Jingsong He; Li Li; Wenjun Wu; Jimin Shi; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 245 KB

## Objective: Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (mm) with an overall response rate of 92% and a cr rate of 18% (alexanian et al, hematology 2007;12(3):235-9), but this regimen has not been tested in the chinese patients. we re

Thalidomide–dexamethasone as primary the
Thalidomide–dexamethasone as primary therapy for advanced multiple myeloma
✍ Michael Wang; Donna M. Weber; Kay Delasalle; Raymond Alexanian 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 1 views

## Abstract The value of thalidomide–dexamethasone was assessed in 26 consecutive, previously untreated patients with multiple myeloma of high tumor mass. All showed Hgb < 8.5 g/dL, serum calcium > 11.5 mg/dL, or both. The response rate was 73%, frequency of early death < 3 months was 5%, projected